Roivant Sciences Ltd. Common Shares (ROIV) Dividend History

Company News

• Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So.

  Moderna's stock has been struggling since the end of the COVID-19 pandemic, with a Wall Street analyst cutting her price target and reiterating a sell recommendation. The analyst cited issues such as cost-management struggles and legal headaches, as well as a hold on a late-stage trial for a norovirus vaccine candidate.

  The Motley Fool

  Featured Companies: ABUS MRNA
• Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

  Organon has completed the acquisition of Dermavant Sciences, a company dedicated to developing and commercializing innovative therapeutic solutions in immuno-dermatology, including the FDA-approved VTAMA® (tapinarof) cream for the treatment of plaque psoriasis.

  Benzinga

  Featured Companies: OGN
• Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates

  Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of 8% and 10.86%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

  Zacks Investment Research

  Featured Companies: MYNZ
• Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update

  BASEL, Switzerland and LONDON and NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2024, and provided a business update.

  GlobeNewswire Inc.
• Wall Street Breakfast: What Moved Markets

  Listen on the go! A daily podcast of Wall Street Breakfast will be available this morning on Seeking Alpha, iTunes, Spotify

  Seeking Alpha

  Featured Companies: ALGN COF CVX ENPH FMC GM GOOG GOOGL HAS HES META NEE PFE ROL RTX SNAP WHR WTW XLC XLE XLK XLU XOM